Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy. Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.
Epistemonikos ID: 85949d16258b95c53882ccb2d26a920a6d0d72c2
First added on: May 06, 2024